Page 10 - குழு க்கு மருத்துவ ப்ராடக்ட்ஸ் மனிதன் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Albireo Pharma, Inc : Albireo Receives Positive CHMP Opinion for Bylvay (odevixibat) for Treatment of Progressive Familial Intrahepatic Cholestasis (PFIC)

- Bylvay has the potential to become first approved drug to treat all forms of PFIC - - CHMP opinion is based on the PEDFIC Phase 3 studies - - PEDFIC 1 met the bile acid (P=0.003) and pruritus

United statesCity ofUnited kingdomColleen alabisoRichard thompsonHans vitzthumRon cooperLisa riveroAlbireo pharma incLifesci advisorsEuropean commissionPediatric committeeResource networkUnited states or european unionExchange commissionCommittee for medicinal products human

Janssen Gets Two Positive CHMP Opinions For Darzalex Subcutaneous Formulation Utilizing Enhanze

Janssen Gets Two Positive CHMP Opinions For Darzalex Subcutaneous Formulation Utilizing Enhanze NEW BRUNSWICK (dpa-AFX) - Janssen Pharmaceutica received two positive opinions from the Committee for Medicinal Products for Human Use or CHMP of the European Medicines Agency or EMA recommending to broaden the existing marketing authorization for the DARZALEX or daratumumab subcutaneous formulation, which uses ENHANZE technology, in two new indications, Halozyme Therapeutics Inc. (HALO) said in a statement. One recommendation is for the use in combination with cyclophosphamide, bortezomib and dexamethasone, for the treatment of adult patients with newly diagnosed systemic light chain amyloidosis. The second recommendation is for the use of daratumumab subcutaneous in combination with pomalidomide and dexamethasone for the treatment of adult patients with multiple myeloma who have received one prior therapy containing a proteasome inhibitor and lenalidomide and were lenalidomide-refract

Janssen pharmaceuticaCommittee for medicinal products humanEuropean medicines agencyHalozyme therapeutics incMedicinal productsHuman useHalozyme therapeuticsகுழு க்கு மருத்துவ ப்ராடக்ட்ஸ் மனிதன்மருத்துவ ப்ராடக்ட்ஸ்மனிதன் பயன்பாடு

PTA-Adhoc: CO DON AG: EU-weit zugelassenes Arzneimittel erhält Votum für Indikationserweiterung zum Einsatz bei Jugendlichen

PTA-Adhoc: CO DON AG: EU-weit zugelassenes Arzneimittel erhält Votum für Indikationserweiterung zum Einsatz bei Jugendlichen
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

Committee for medicinal products humanUdon companyCorporate communications investorAgency gmbh financialPeople publicationInformation articleMedicinal productsNotification to theWas followedIcrs degreesPublic relationsMatthias telRegulated marketAgency gmbh financial andDow jones newswires mayகுழு க்கு மருத்துவ ப்ராடக்ட்ஸ் மனிதன்

Avis positif de l Agence européenne des médicaments pour le traitement anti-covid Sotrovimab à base d anticorps monoclonaux

Avis positif de l Agence européenne des médicaments pour le traitement anti-covid Sotrovimab à base d anticorps monoclonaux
rtbf.be - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from rtbf.be Daily Mail and Mail on Sunday newspapers.

New yorkUnited statesCommittee for medicinal products humanCommittee for medicinal productsEuropean medicinesVir biotechnologyMember statesMedicinal productsHuman useபுதியது யார்க்ஒன்றுபட்டது மாநிலங்களில்குழு க்கு மருத்துவ ப்ராடக்ட்ஸ் மனிதன்குழு க்கு மருத்துவ ப்ராடக்ட்ஸ்ஐரோப்பிய மருந்துகள்வீர் உயிரி தொழில்நுட்பவியல்உறுப்பினர் மாநிலங்களில்

NanoViricides Has Filed Quarterly Report for Period Ending March 31, 2021 - Has Sufficient Cash, Coronavirus Drug Candidate Moving Towards IND

NanoViricides Has Filed Quarterly Report for Period Ending March 31, 2021 - Has Sufficient Cash, Coronavirus Drug Candidate Moving Towards IND ACCESSWIRE 17 May 2021, 20:55 GMT+10 SHELTON, CT / ACCESSWIRE / May 17, 2021 / NanoViricides, Inc. (NYSE American:NNVC) (the Company ) a global leader in the development of highly effective antiviral therapies based on a novel nanomedicines platform (the Company ), has filed its quarterly report for its third quarter of financial year 2021 with the Securities and Exchange Commission. This press release should be read in conjunction with the Company s Form 10-Q filed on May 14, 2021. The submission can be downloaded from the SEC website at: https://www.sec.gov/Archives/edgar/data/1379006/000110465921066909/tm2111798d1 10q.htm.

South africaUnited statesUnited kingdomSouth africanNanoviricides incDrug administrationCompany formExchange commissionCommittee for medicinal products humanTheracour pharma incEuropean medicines agencySecurities exchangeHuman immunodeficiency virusHepatitisb virusHepatitisc virusHerpes simplex virus